@article{78680c4c42b741588a724b4d60dc8db5,
title = "Pilot study: Fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer",
abstract = "Objective: To evaluate the safety, tolerability, and benefit of fluvoxamine for the treatment of major depressive disorder or anxiety disorders in children and adolescents with cancer. Method: The study was conducted from 2001 to 2004 at a pediatric hematology-oncology center. Fifteen children and adolescents with cancer were treated with fluvoxamine 100 mg/day in an open prospective 8-week trial. Safety and tolerability were evaluated at baseline and at weeks 4 and 8 by blood tests and the Side Effects Checklist. Clinical benefit was assessed with the Clinical Global Impressions-Improvement, the Children's Depression Rating Scale-Revised, and the Pediatric Anxiety Rating Scale. Results: Fluvoxamine was well tolerated by all subjects. Psychiatric symptoms improved significantly. Conclusions: In this open trial, fluvoxamine appeared to be well tolerated and was associated with a promising reduction in the depression and anxiety symptoms of pediatric patients with cancer.",
keywords = "Antidepressants, Cancer, Depression, Fluvoxamine",
author = "Doron Gothelf and Maly Rubinstein and Eyal Shemesh and Orit Miller and Ilana Farbstein and Anat Klein and Abraham Weizman and Alan Apter and Isaac Yaniv",
year = "2005",
month = dec,
doi = "10.1097/01.chi.0000181042.29208.eb",
language = "אנגלית",
volume = "44",
pages = "1258--1262",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Inc.",
number = "12",
}
